Posted by Michael Wonder on 19 Oct 2020
Glenmark Pharmaceuticals receives ANDA approval for sirolimus 0.5 mg, 1 mg and 2 mg tablets
19 October 2020 - Glenmark Pharmaceuticals has received final approval by the United States FDA for sirolimus 0.5 mg, 1 mg and 2 mg tablets, the generic version of Rapamune 0.5 mg, 1 mg and 2 mg tablets of PF Prism CV.
According to IQVIA sales data for the 12 month period ending August 2020, the Rapamune 0.5 mg, 1 mg and 2 mg tablets market achieved annual sales of approximately $119.7 million.
